Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Energy metabolism in IDH1 wild-type and IDH1-mutated glioblastoma stem cells : a novel target for therapy?
Authors:ID Noorden, Cornelis J. F. van (Author)
ID Hira, Vashendriya V. V. (Author)
ID Dijck, Amber J. van (Author)
ID Novak, Metka (Author)
ID Breznik, Barbara (Author)
ID Molenaar, Remco J. (Author)
Files:URL URL - Source URL, visit https://www.mdpi.com/2073-4409/10/3/705
 
.pdf PDF - Presentation file, download (3,87 MB)
MD5: FF27FE913BF90B0ECDA88817C2A3FEF6
 
URL URL - Source URL, visit https://doi.org/10.3390/cells10030705
 
Language:English
Typology:1.02 - Review Article
Organization:Logo NIB - National Institute of Biology
Abstract:Cancer is a redox disease. Low levels of reactive oxygen species (ROS) are beneficial for cells and have anti-cancer effects. ROS are produced in the mitochondria during ATP production by oxidative phosphorylation (OXPHOS). In the present review, we describe ATP production in primary brain tumors, glioblastoma, in relation to ROS production. Differentiated glioblastoma cells mainly use glycolysis for ATP production (aerobic glycolysis) without ROS production, whereas glioblastoma stem cells (GSCs) in hypoxic periarteriolar niches use OXPHOS for ATP and ROS production, which is modest because of the hypoxia and quiescence of GSCs. In a significant proportion of glioblastoma, isocitrate dehydrogenase 1 (IDH1) is mutated, causing metabolic rewiring, and all cancer cells use OXPHOS for ATP and ROS production. Systemic therapeutic inhibition of glycolysis is not an option as clinical trials have shown ineffectiveness or unwanted side effects. We argue that systemic therapeutic inhibition of OXPHOS is not an option either because the anti-cancer effects of ROS production in healthy cells is inhibited as well. Therefore, we advocate to remove GSCs out of their hypoxic niches by the inhibition of their binding to niches to enable their differentiation and thus increase their sensitivity to radiotherapy and/or chemotherapy.
Keywords:glioblastoma stem cells, IDH1-mutation, energy metabolism
Publication status:Published
Publication version:Version of Record
Publication date:22.03.2021
Year of publishing:2021
Number of pages:str. 1-15
Numbering:Vol. 10, iss. 3
PID:20.500.12556/DiRROS-20108 New window
UDC:577.2
ISSN on article:2073-4409
DOI:10.3390/cells10030705 New window
COBISS.SI-ID:59095043 New window
Note:Nasl. z nasl. zaslona; Opis vira z dne 12. 4. 2021;
Publication date in DiRROS:05.08.2024
Views:30
Downloads:12
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Cells
Shortened title:Cells
Publisher:MDPI
ISSN:2073-4409
COBISS.SI-ID:519958809 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J3-2526-2020
Name:Razkrivanje niše matičnih glioma celic v iskanju novih terapevtskih ciljev pri bolnikih z glioblastomom

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:Z3-1870-2019
Name:Vpliv mezenhimskih matičnih celic na odpornost glioblastoma na terapijo

Funder:Other - Other funder or multiple funders
Funding programme:the Dutch Cancer Society
Project number:UVA 2014-6839

Funder:Other - Other funder or multiple funders
Funding programme:the Dutch Cancer Society
Project number:UVA 2016.1-10460

Funder:Other - Other funder or multiple funders
Name:the Fondation pour la Recherche Nuovo-Soldati 2019

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Back